Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Suven Life Sciences is currently trading at Rs 17.80, up by 0.55 points or 3.19% from its previous closing of Rs 17.25 on the BSE.
The scrip opened at Rs 17.00 and has touched a high and low of Rs 18.15 and Rs 16.90 respectively. So far 48701 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 1 has touched a 52 week high of Rs 33.55 on 08-Nov-2010 and a 52 week low of Rs 15.00 on 09-Aug-2011.
Last one week high and low of the scrip stood at Rs 18.50 and Rs 16.95 respectively. The current market cap of the company is Rs 210.12 crore.
The promoters holding in the company stood at 63.28% while Institutions and Non-Institutions held 0.38% and 36.33% respectively.
Suven Life Sciences has secured grant of four product patents, one from Europe, two from New Sri Lanka and one from Korea corresponding to the New Chemical Entities (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2027, 2025 and 2024 respectively.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) , Huntingon’s disease, Parkinson and Schizophrenia.
With these patents, Suven has a total of eleven granted patents from Europe, eight granted patents from Sri Lanka, five granted patents from Korea for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |